6 Foods That Lower Testosterone Levels

Certain herbs, seeds, and beverages, among other foods, may lower testosterone levels, which can affect muscle mass, sexual function, and overall strength.
Testosterone is a sex hormone that plays a decisive role in health.
It's estimated that 1.2–12.8% of males have low testosterone levels, also known as hypogonadism.
Low testosterone levels may put you at risk of developing a number of health conditions, including:
obesity
metabolic syndrome
type 2 diabetes
cardiovascular disease
osteoporosis
Many factors are involved in regulating testosterone, but a healthy diet may help you keep your levels in check.
Here are six foods that may help lower your testosterone levels.
A note on sex and gender
We use 'women' and 'men' in this article to reflect the terms that have been used in the cited research. That said, your gender identity may not align with how your body responds to lower levels of testosterone. A doctor can better help you understand how your specific circumstances will translate into diagnosis, symptoms, and treatment.
1. Mint
Research suggests that mint may cause a dip in testosterone levels.
In particular, spearmint and peppermint —two herbs from the mint family of plants—have been shown to directly affect testosterone.
One 12-week study of 150 subjects, divided between a group with polycystic ovary syndrome (PCOS) and a control group without it, showed that drinking spearmint herbal tea daily caused a significant decline in testosterone levels, with a slightly greater decline for the individuals with PCOS.
Similarly, an animal study found that administering spearmint essential oil to rats for 20 days resulted in reduced testosterone levels.
However, most research on mint and testosterone focuses on women or animals.
High-quality human studies focusing on all sexes assigned at birth are needed to assess how mint affects testosterone levels in both males and females.
2. Licorice root
Licorice root is an ingredient commonly used to sweeten candies and beverages.
It's also a popular natural remedy in holistic medicine and is used to help treat everything from common colds to chronic pain.
In recent years, several studies have found that licorice may also influence hormone levels, potentially leading to a decline in testosterone over time.
In a 2003 study, 25 men consumed 7 grams of licorice root daily, which caused a 26% drop in testosterone levels after just 1 week.
Another older study showed that licorice may reduce testosterone levels in women as well, reporting that 3.5 grams of licorice daily decreased testosterone levels by 32% after just one menstrual cycle.
That said, a recent 2021 animal study found that licorice extract helped raise testosterone levels in mice who were injected with methotrexate, which lowered testosterone levels.
Newer research in humans is needed to further support the effects of licorice root on testosterone.
It's also important to note that this applies to licorice root rather than licorice candy, which often doesn't contain any licorice root.
3. Flaxseed
Flaxseed is packed with heart-healthy fats, fiber, and various important vitamins and minerals.
In addition, some research shows that it may cause a decrease in testosterone levels in certain populations.
This is because flaxseed is high in lignans, which are plant compounds that bind to testosterone and force it to be excreted from your body.
Furthermore, flaxseed is rich in omega-3 fatty acids, which may also be linked to a decrease in testosterone.
In a 2001 study of 25 men with prostate cancer, supplementing with flaxseed and decreasing overall fat intake was shown to significantly reduce testosterone levels.
Similarly, a case study reported daily flaxseed supplements decreased testosterone levels in a 31-year-old woman with polycystic ovary syndrome, a condition characterized by increased male hormones.
However, more large-scale studies are needed to further evaluate the effects of flaxseed on testosterone levels.
4. Trans fats
Trans fats are an unhealthy type of fat that has been banned in the United States since 2015, but may be present in some imported or older products. These fats have been linked to an increased risk of heart disease, type 2 diabetes, and inflammation.
Plus, some studies have found that regularly consuming trans fats from sources like processed foods could decrease testosterone levels.
For example, one study of 209 men showed that those who consumed the highest amounts of trans fats had 15% lower testosterone levels than those with the lowest intake.
Animal studies have also found that a high intake of trans fats could lower testosterone levels and even impair reproductive performance.
5. Alcohol
While enjoying the occasional glass of wine with dinner has been linked to health benefits, a small 2004 study in 19 healthy adults showed that consuming 30–40 grams of alcohol per day, which equates to about 2–3 standard drinks, decreased testosterone levels in men by 6.8% over 3 weeks.
Another study in 2014 reported that alcohol consumption reduced semen and changed reproductive hormones in young Danish men.
However, the evidence isn't entirely clear-cut when it comes to the effects of alcohol on testosterone.
In fact, both human and animal studies have had mixed results, with some research indicating that alcohol could actually increase testosterone levels in certain cases.
Further research is needed to understand how different doses of alcohol affect testosterone levels in the general population.
6. Nuts
Nuts are a great source of many important nutrients, including fiber, heart-healthy fats, and minerals like folic acid, selenium, and magnesium.
However, some studies suggest that certain types of nuts may decrease testosterone levels.
One small study in 31 women with polycystic ovary syndrome showed that walnuts and almonds increased levels of sex hormone-binding globulin (SHBG) by 12.5% and 16%, respectively.
SHBG is a type of protein that binds to testosterone, which can lead to a decrease in the levels of free testosterone in your body.
Nuts are also generally high in polyunsaturated fatty acids, which have been associated with decreased testosterone levels in some older studies.
Despite these findings, more research is needed to determine if and how certain types of nuts may affect testosterone levels.
In the meantime, current research supports nut intake for cardiovascular and endocrine health unless you have an allergy.
What about soy?
There is a common belief that regularly eating soy products like edamame, tofu, and soy milk may cause a drop in testosterone levels.
One older rat study from 2001 seemed to show that consuming phytoestrogens significantly decreased testosterone levels and prostate weight.
However, more recent human studies have found that soy foods did not affect testosterone levels in men.
While more research is needed to confirm, the belief that soy products affect testosterone appears to have been debunked.
Frequently asked questions
What foods decrease testosterone?
Research in both animals and humans suggests that certain foods may decrease your levels of testosterone. These include:
mint
nuts
alcohol
trans fats
flaxseed
licorice root
It's important to note that more studies with humans are needed to better support these findings.
Research in both animals and humans suggests that certain foods may decrease your levels of testosterone. These include:
mint
nuts
alcohol
trans fats
flaxseed
licorice root
It's important to note that more studies with humans are needed to better support these findings.
Do eggs lower testosterone?
Eggs are a great source of omega-3 fats, protein, and vitamins. Their yolks are also rich in selenium, which is a mineral that acts as an antioxidant in your body.
One review of animal test-tube studies suggests that selenium may enhance testosterone production.
Another study found that egg white powder helped increase testosterone levels in men with obesity.
Although more research is needed, whole eggs are very nutritious foods.
Eggs are a great source of omega-3 fats, protein, and vitamins. Their yolks are also rich in selenium, which is a mineral that acts as an antioxidant in your body.
One review of animal test-tube studies suggests that selenium may enhance testosterone production.
Another study found that egg white powder helped increase testosterone levels in men with obesity.
Although more research is needed, whole eggs are very nutritious foods.
What food has the highest testosterone?
Certain foods may boost your levels of testosterone more than others, including:
fatty fish
dark, leafy greens
avocados
cocoa products
berries
shellfish
Certain foods may boost your levels of testosterone more than others, including:
fatty fish
dark, leafy greens
avocados
cocoa products
berries
shellfish
Takeaway
Modifying your diet is a great way to help maintain healthy testosterone levels.
If you're concerned about low testosterone levels, swapping out these testosterone-lowering foods and replacing them with healthy, whole-food alternatives may help keep levels in check and enhance your overall health.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medscape

22 minutes ago

• Medscape

Fewer ECG Abnormalities in Early T2D With Combo Therapy

TOPLINE: In patients with type 2 diabetes (T2D) of less than 10 years' duration who were taking metformin monotherapy, ECG abnormalities — including evidence of cardiovascular autonomic neuropathy — were common and associated with cardiovascular risk factors. After adding one of four frequently used glucose-lowering agents to metformin, fewer major ECG changes occurred with liraglutide than with the other treatments. METHODOLOGY: Researchers aimed to examine ECG abnormalities and cardiovascular autonomic neuropathy across the different glucose-lowering treatment groups in 5029 participants (mean age, 57.2 years; diabetes duration, 4.2 years; A1c level, 7.5%; 36.4% women) from the GRADE trial. The participants had T2D for less than 10 years and were initially taking metformin monotherapy before being randomly assigned to receive metformin plus one of four commonly used glucose-lowering agents (insulin glargine, glimepiride, liraglutide, or sitagliptin). Patients were followed up for an average of 5 years. Resting ECGs were recorded at baseline and at 2‐ and 4‐year follow-ups and analyzed for overall, major, and minor abnormalities, as well as heart rate variability — a measure of cardiovascular autonomic neuropathy. TAKEAWAY: More than half of participants in the GRADE trial had ECG abnormalities (57.1%) and ECG-defined cardiovascular autonomic neuropathy (52.8%) at baseline. The presence of these abnormalities was associated with longer diabetes duration, higher systolic blood pressure, greater prevalence of hyperlipidemia, more frequent use of lipid-lowering treatment, and beta-blocker use. Major ECG abnormalities occurred less frequently in the liraglutide group than in the other treatment groups (9% vs 13% at 4 years). Researchers found no significant differences in ECG-defined cardiovascular autonomic neuropathy between the liraglutide and non-liraglutide groups at 2 and 4 years (P = .42). IN PRACTICE: "ECG abnormalities, including those of CAN [cardiovascular autonomic neuropathy], are common in T2D < 10 years and are associated with certain CV [cardiovascular] risk factors. The development of major ECG abnormalities may differ by glucose-lowering treatment, as fewer occurred with liraglutide vs the other treatments," the authors concluded. SOURCE: The study was led by Rodica Pop-Busui, MD, PhD, Oregon Health & Science University in Portland. The results were presented on June 20 at the American Diabetes Association (ADA) 85th Scientific Sessions, being held June 20-23 at the McCormick Place Convention Center in Chicago, Illinois. LIMITATIONS: This abstract did not discuss any limitations. DISCLOSURES: Some authors disclosed receiving research support, consulting fees; serving on boards, advisory panels; being stock/shareholders; or other relationships with pharmaceutical and diagnostics companies and institutions. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Yahoo

36 minutes ago

• Yahoo

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin. The complete results from these studies were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025. Simultaneously, results from QWINT-1, a first-of-its-kind fixed-dose study, were published in The New England Journal of Medicine, while results from QWINT-3 and QWINT-4 were published in The Lancet. In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.1,2 In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.3 In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand.4 In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine at week 26 for the efficacy estimand.5 In these two trials, efsitora was administered using traditional insulin dosing with adjustments based on each patient's glucose level. "The novel fixed-dose regimen used in QWINT-1 for once-weekly efsitora, which consisted of only four single-dose titration options, has the potential to facilitate and simplify insulin therapy, reducing the hesitation often associated with starting insulin to treat type 2 diabetes," said Dr. Julio Rosenstock, senior scientific advisor for Velocity Clinical Research at Medical City Dallas, clinical professor of medicine, University of Texas Southwestern Medical Center, and lead trial investigator for QWINT-1. "A simpler, once-weekly regimen with efsitora may help people with type 2 diabetes initiate and manage insulin therapy with the goal of improving blood sugar levels. Across all QWINT trials, the results showed that once-weekly efsitora controlled glucose as effectively as the most popular once-daily basal insulins." QWINT-1 Primary EndpointEfficacy Estimand Treatment-RegimenEstimand6 Primary Endpoint – A1C Reduction (Resulting A1C) at Week 52 Efsitora -1.31 % (6.92 %) -1.19 % (7.05 %) Glargine -1.27 % (6.96 %) -1.16 % (7.08 %)QWINT-3 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-RegimenEstimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -0.86 % (6.93 %) -0.81 % (6.99 %) Degludec -0.75 % (7.03 %) -0.72 % (7.08 %) Key Secondary Endpoint – Rates of Clinically Significant or Severe Nocturnal Hypoglycemic Events Per Patient-Year of Exposure up to Week 787,8 Efsitora 0.11 Degludec 0.10 Key Secondary Endpoint – Percent Time in Range (70-180 mg/dL) During the FourWeeks Prior to Week 26 Efsitora 62.8 % 61.4 % Degludec 61.3 % 61.0 %QWINT-4 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-Regimen Estimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -1.07 % (7.12 %) -1.01 % (7.17 %) Glargine -1.07 % (7.11 %) -1.00 % (7.18 %) Key Secondary Endpoint – Participants Achieving A1C <7% at Week 26 Without Nocturnal Hypoglycemia Efsitora 39.5 % 38.6 % Glargine 36.6 % 35.9 % Key Secondary Endpoint – Rates of Clinically Significant or Severe NocturnalHypoglycemic Events Per Patient-Year of Exposure up to Week 26 Efsitora 0.67 Glargine 1.00 "Building on Lilly's legacy of innovation in insulin therapy, once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year," said Jeff Emmick, M.D., Ph.D., senior vice president of product development at Lilly. "These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach. We look forward to working with regulatory agencies to bring this innovation to patients around the world." Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for the treatment of type 2 diabetes. In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks. In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with efsitora vs. 5.9 with insulin glargine at 26 weeks. Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year. About the QWINT clinical trial programThe QWINT Phase 3 global clinical development program for insulin efsitora alfa (efsitora) in diabetes began in 2022 and has enrolled more than 3,000 people living with type 2 diabetes across four global registration studies. QWINT-1 (NCT05662332) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin using a fixed dose escalation to daily insulin glargine for 52 weeks in insulin-naïve adults with type 2 diabetes. The trial randomized 795 participants across the U.S., Argentina and Mexico to receive efsitora once weekly or insulin glargine once daily, administered subcutaneously. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 52 with efsitora compared to daily use of insulin glargine. QWINT-3 (NCT05275400) was a multicenter, randomized, parallel-design, open-label trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin to insulin degludec for 78 weeks after a three-week lead-in followed by a five-week safety follow up period, in adults with type 2 diabetes who are currently treated with basal insulin. The trial randomized 986 participants across the U.S., Argentina, Hungary, Japan, Korea, Poland, Puerto Rico, Slovakia, Spain and Taiwan to receive efsitora once weekly or insulin degludec once daily, administered subcutaneously. The primary objective of the study was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin degludec. QWINT-4 (NCT05462756) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a weekly basal insulin to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized 730 participants across the U.S., Argentina, Germany, India, Italy, Mexico, Puerto Rico and Spain to receive efsitora once weekly or insulin glargine once daily, both of which were administered subcutaneously along with insulin lispro. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin glargine. About insulin efsitora alfaInsulin efsitora alfa (efsitora) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. P-LLY The efficacy estimand represents the treatment effect on all participants who adhered to the study drug without initiating rescue therapy for persistent severe hyperglycemia. From a baseline of 8.20% for efsitora and 8.28% for insulin glargine. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. From a baseline of 7.80% for both efsitora and insulin degludec. From a baseline of 8.18% for both efsitora and insulin glargine. The treatment-regimen estimand represents the estimated average treatment effect regardless of treatment discontinuation or introduction of rescue therapy for persistent severe hyperglycemia. Blood glucose <54 mg/dL. Nocturnal hypoglycemia was defined as any event that occurred at night between midnight and 6 a.m. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about insulin efsitora alfa as a potential treatment for people with type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to insulin efsitora alfa and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study results to date, that insulin efsitora alfa will prove to be a safe and effective treatment for type 2 diabetes, that insulin efsitora alfa will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Refer to: Niki Biro; niki_biro@ 317-358-9074 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CBS News

an hour ago

• CBS News

Annual Fight For Air Climb at Soldier Field raises over $350K for lung health

Despite the heat in Chicago, climbers took to Soldier Field for the annual Fight For Air Climb event to raise thousands of dollars for lung health. Over 700 people from different skill levels participated in Sunday morning's event, presented by UnitedHealthcare, to raise money for research, education, and advocacy. In the end, they raised over $350,000. The climb helps support the over 1.4 million people living with lung disease in Illinois. Due to the weekend's dangerous weather, organizers had changed the original 1,600-step route and added portable misting fans. The heat, however, didn't stop the Firefighter Challenge as teams of firefighters climbed in full gear. The American Lung Association said it looks forward to next year's event and "continuing its commitment to improving lung health and preventing lung disease."